Sleep and health tracking ring startup Oura raises $100M Series C, valuing the company at $800M, and says its ~$30M in 2019 sales doubled in 2020
Alex Konrad / Forbes : Tweets: @alexrkonrad Tweets: Alex Konrad / @alexrkonrad : Oura, the sleep-tracking ring that was once a Kickstarter project, has raised $100M at an $800M valuation to move further into personalized health. New investors include Temasek and The Chernin Group. @katiedjennings and I spoke to Oura about the raise: https://www.forbes.com/...
Context & Ripple Effects
This raise is the middle rung of a funding ladder the coverage traces end to end: Oura went from a $28M Series B in March 2020 — with Google's Gradient Ventures, Square, and Forerunner on the cap table and 150K rings sold — to this $100M Series C at $800M just over a year later, with sales doubling from ~$30M in 2019 through 2020. New investors Temasek and The Chernin Group signal the company is being repositioned from sleep gadget to personalized-health platform.
What makes the Series C worth reading backward from is where it landed: the same company later raised a $200M Series D from Fidelity and Dexcom at $5.2B, then an $875M+ Series E at $10.9B, with cumulative ring sales climbing past 2.5M along the way. The 2021 round is the inflection where the smart ring stopped being a niche wearable and became a venture-scale asset.
First-order effects
- Oura gains $100M and a $800M valuation from Temasek and The Chernin Group to fund its stated push from sleep tracking into broader personalized health — capital that arrives on the back of 2020 revenue roughly doubling 2019's ~$30M.
Second-order effects
- The round validates the smart-ring category for institutional capital: a year later Oura raised again at a $2.55B valuation with over 1M rings sold, and Dexcom's later Series D investment points to health-device incumbents buying into the ring as a sensing platform rather than dismissing it.
Third-order effects
- The pattern — valuation compounding from $800M to $5.2B to $10.9B in four years on doubling sales — sets up the endgame the coverage confirms: Oura filing confidential IPO paperwork, with the Series C as the round that made a public listing plausible.
The trend: Consumer health wearables are consolidating around venture-funded platform companies whose valuations compound on subscription-style health data, with the public markets as the intended exit.